August 29, 2024 02:16 PM EDT
FDA+
Law

FDA hints at what Chevron's elim­i­na­tion means in new SCO­TUS fil­ing

Zachary Brennan

Senior Editor

Ear­li­er this sum­mer, when the Supreme Court elim­i­nat­ed a long­stand­ing le­gal doc­trine that de­ferred to fed­er­al agen­cies on in­ter­pret­ing fed­er­al law, many le­gal ob­servers said …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster

Doug Williams re­turns with a ‘FIT’ bet on CAR-Ts; Bio­gen ap­points Mene Pan­ga­los to board

Af­ter a huge IPO and ac­qui­si­tion, Zymer­gen caps off bank­rupt­cy with $30M SEC penal­ty

Cor­rect­ed: Roche’s Tecen­triq scores first US ap­proval for sub­cu­ta­neous PD-L1

A service from the Financial Times